Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Wednesday, Sep 06, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Overall, patients with HER2-positive breast cancer do well with available regimens. Using trastuzumab (Herceptin) in combination with chemotherapy for this patient population significantly improves disease-free and overall survival, states Tolaney.

How to best add pertuzumab (Perjeta) to the treatment landscape and which patients should receive it are significant questions that many physicians would like to see answered, explains Tolaney.

SELECTED
LANGUAGE


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Overall, patients with HER2-positive breast cancer do well with available regimens. Using trastuzumab (Herceptin) in combination with chemotherapy for this patient population significantly improves disease-free and overall survival, states Tolaney.

How to best add pertuzumab (Perjeta) to the treatment landscape and which patients should receive it are significant questions that many physicians would like to see answered, explains Tolaney.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x